Q3 2023 Results

Company overview Innovation: Pipeline overview Financial review Financial performance Novartis pipeline in Phase 1 Oncology Code Indication(s) Name Mechanism Solid tumors AAA603 177Lu-NeoB AAA614 AAA817 DFF332 DFF332 HRO761 HRO761 IAG933 IAG933 KFA115 KFA115 MGY825 MGY825 NZV930 NZV930 QEQ278 QEQ278 AAA614 225AC-PSMA-617 Radioligand therapy target GRPR Radioligand therapy target FAP Radioligand therapy target PSMA HIF2A inhibitor Werner inhibitor Multiple solid tumors Breast cancer Solid tumors Metastatic castration-resistant prostate cancer Renal cell carcinoma Novel immunomodulatory Agent CD73 antagonist NKG2D/-L pathway modulator Solid tumors Mesothelioma Solid tumors NSCLC Solid tumors Solid tumors Hematology DFV890 DFV890 sabatolimab PIT565 MBG453 PIT565 YTB323 NLRP3 inhibitor TIM3 antagonist rapcabtagene autoleucel CD19 CAR-T Neuroscience Low risk myelodysplastic syndrome Low risk myelodysplastic syndrome B-cell malignancies Adult ALL Code Name DFT383 DFT383 NIO752 NIO752 Mechanism CTNS gene delivery Tau antisense oligonucleotide Indication(s) Cystinosis pre/post kidney transplant Alzheimer's disease Progressive supranuclear palsy Cardiovascular Code Name XXB750 XXB750 Mechanism NPR1 agonist 34 Investor Relations | Q3 2023 Results Indication(s) Heart failure Conclusions Appendix Innovation: Clinical trials Immunology References Abbreviations INNOVATION 16 lead indications Code Name MHV370 MHV370 Mechanism TLR7, TLR8 Antagonist Indication(s) Systemic lupus erythematosus Others Name Mechanism Code IB&GH EDI048 EDI048 EYU688 EYU688 INE963 INE963 CpPI(4)K inhibitor NS4B inhibitor Indication(s) Cryptosporidiosis Dengue Malaria, uncomplicated Lead indication NOVARTIS | Reimagining Medicine

View entire presentation